As life-sav­ing check­point drugs move to ear­li­er can­cers, re­searchers de­bate how best to use them

CHICA­GO — Check­point ther­a­pies, which made their name as treat­ments for pa­tients with metasta­t­ic can­cer, are now be­ing im­ple­ment­ed in a wide range of less-ad­vanced can­cers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER